US Drug Prices: A Mixed Reality
The TrumpRx site launched in January with a promise of cheaper medicines for Americans. A recent check shows that about one third of the 54 drugs listed are actually cheaper in Britain. The UK, which also struck a deal to keep U.S. drug tariffs out of the way, pays 67 % to 82 % less for drugs like Pfizer’s arthritis pill Xeljanz, AstraZeneca’s diabetes medicine Farxiga and GSK’s lung inhalers.
Trump’s Bold Claims vs. Reality
President Trump has bragged that the website proves he can cut U.S. drug costs “from the highest to the lowest,” even claiming some medicines are now 300 % to 600 % cheaper. Those numbers don’t line up with the actual prices, and critics point out that TrumpRx shows only a rough ceiling on what cash‑paying patients might spend. Most Americans use insurance, so the real out‑of‑pocket costs are different.
Where Savings Are Most Dramatic
| Category | Drug | Old Price | New Price (TrumpRx) |
|---|---|---|---|
| Weight‑loss injections | Eli Lilly’s Zepbound | >$1,000/month | $149–$350 |
| Weight‑loss injections | Novo Nordisk’s Wegovy | >$1,000/month | $149–$350 |
| Fertility | EMD Serono’s fertility drugs | — | 84 % discount |
The U.K. NHS sets prices through cost‑control deals and a flat prescription charge of £9.90 in England, while prescriptions are free elsewhere.
Drugmakers’ Reactions
| Company | Position |
|---|---|
| Novartis & Roche (Swiss) | Deals won’t hurt them |
| Novo Nordisk | Sales could drop 13 % next year |
| Johnson & Johnson | Hit of hundreds of millions, but impact small due to high volume |
The key factor is how much a company sells through government programs versus private sales.
Expert Take
Experts say the voluntary nature of the deals means there is no real enforcement, so they may not solve the broader problem of high drug prices. The U.K.’s approach relies on negotiating lower prices directly with manufacturers—a strategy that seems to yield better results for many patients.
Bottom Line
While TrumpRx showcases some impressive price reductions, the overall impact on U.S. patients—especially those with insurance—is limited. The comparison to U.K. prices highlights that a more systematic approach, like the U.K.’s direct negotiations, may be necessary to bring down drug costs across the board.
